Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?
Laryngoscope
.
2023 Jan;133(1):2-3.
doi: 10.1002/lary.30180.
Epub 2022 May 11.
Authors
Craig S Derkay
1
,
Emily E Wikner
2
,
Seth Pransky
3
,
Simon R Best
4
,
Karen Zur
5
,
Douglas R Sidell
6
,
Adam Klein
7
,
Clark Rosen
8
,
Frederick G Dikkers
9
,
Romaine Johnson
10
Affiliations
1
Departments of Otolaryngology and Pediatrics, Eastern Virginia Medical School, Children's Hospital of the King's Daughters, Norfolk, Virginia, USA.
2
Department of Otolaryngology, Eastern Virginia Medical School, Norfolk, Virginia, USA.
3
Pediatric Specialty Partners of San Diego, San Diego, California, USA.
4
Depatment of Otolaryngology, Johns Hopkins University, Baltimore, Maryland, USA.
5
Depatment of Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
6
Depatment of Otolaryngology, Stanford University, Palo Alto, California, USA.
7
Depatment of Otolaryngology, Emory University, Atlanta, Georgia, USA.
8
Depatment of Otolaryngology, University of California, San Francisco, California, USA.
9
Depatment of Otolaryngology, Amsterdam University Medical Center, Amsterdam, NL, USA.
10
Depatment of Otolaryngology, University of Texas-Southwestern, Dallas, Texas, USA.
PMID:
35543118
PMCID:
PMC10084367
DOI:
10.1002/lary.30180
No abstract available
MeSH terms
Bevacizumab / therapeutic use
Humans
Papillomavirus Infections* / drug therapy
Respiratory Tract Infections* / drug therapy
Substances
Bevacizumab
Supplementary concepts
Recurrent respiratory papillomatosis